临床实践指南:吸入性过敏原免疫治疗
该指南由耳鼻咽喉头颈外科领域制定,针对5岁及以上过敏性鼻炎伴或不伴过敏性哮喘患者,提出吸入性过敏原免疫治疗的推荐意见,涵盖患者选择、安全性评估、患者教育、治疗方案及疗程等关键环节。
要点
- 进行过敏原皮肤试验或施用免疫治疗的临床医生必须能够诊断和处理过敏性休克(强推荐)。
- 对妊娠、未控制哮喘或无法耐受注射肾上腺素的患者,不应启动过敏原免疫治疗(推荐)。
- 对免疫治疗应答良好的患者,治疗至少持续3年,具体时长依据患者反应而定(推荐)。
核心结论
- 指南旨在识别质量改进机会,为吸入性过敏的免疫治疗管理提供可信的循证推荐,优化患者照护、促进安全有效治疗、减少不当差异并降低伤害风险。
- 指南针对5岁及以上过敏性鼻炎伴或不伴过敏性哮喘、适合或正在接受免疫治疗的患者,面向所有参与免疫治疗实施的临床医生。
研究设计与样本
- 指南制定小组(GDG)基于循证方法制定临床实践指南,聚焦其判断最重要的质量改进机会,并非吸入性过敏免疫治疗管理的全面通用指南。
- 指南声明不限制临床医生基于经验和个体患者评估提供的照护。
主要发现
- 指南制定小组就关键行动声明(KAS)10做出强推荐:进行过敏原皮肤试验或施用免疫治疗的临床医生必须能够诊断和处理过敏性休克。
- 指南制定小组就以下KAS做出推荐:KAS 1、2A、3、4、5、6、7、9、11、12;并就KAS 2B和8提供选项。
关键数值与推荐
- KAS 1(推荐):对药物治疗、过敏原回避或两者均不能充分控制症状,或偏好免疫调节的过敏性鼻炎伴或不伴过敏性哮喘患者,临床医生应提供免疫治疗或转诊至能提供免疫治疗的临床医生。
- KAS 2A(推荐):对妊娠、未控制哮喘或无法耐受注射肾上腺素的患者,临床医生不应启动过敏原免疫治疗。
- KAS 2B(选项):对使用β受体阻滞剂、有过敏性休克史、存在全身免疫抑制或嗜酸性食管炎(仅皮下免疫治疗)的患者,临床医生可选择不启动过敏原免疫治疗。
- KAS 3(推荐):临床医生应在启动免疫治疗前评估或转诊评估哮喘症状和体征,并在后续免疫治疗给药前评估未控制哮喘的症状和体征。
- KAS 4(推荐):临床医生应向免疫治疗候选患者教育皮下免疫治疗与舌下免疫治疗(水剂和片剂)在风险、获益、便利性和费用方面的差异。
临床怎么用
- 临床医生应依据指南推荐,在启动免疫治疗前评估哮喘症状和体征,并向患者教育皮下与舌下免疫治疗的差异及免疫治疗的潜在获益。
- 对症状控制良好的免疫治疗患者,应治疗至少3年,持续时长基于患者反应;重复过敏检测不应用于评估持续免疫治疗疗效,除非环境暴露改变或症状控制丧失。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Allergen immunotherapy (AIT) is the therapeutic exposure to an allergen or allergens selected by clinical assessment and allergy testing to decrease allergic symptoms and induce immunologic tolerance. Inhalant AIT is administered to millions of patients for allergic rhinitis (AR) and allergic asthma (AA) and is most commonly delivered as subcutaneous immunotherapy (SCIT) or sublingual immunotherapy (SLIT). Despite its widespread use, there is variability in the initiation and delivery of safe and effective immunotherapy, and there are opportunities for evidence-based recommendations for improved patient care. PURPOSE: The purpose of this clinical practice guideline (CPG) is to identify quality improvement opportunities and provide clinicians trustworthy, evidence-based recommendations regarding the management of inhaled allergies with immunotherapy. Specific goals of the guideline are to optimize patient care, promote safe and effective therapy, reduce unjustified variations in care, and reduce the risk of harm. The target patients for the guideline are any individuals aged 5 years and older with AR, with or without AA, who are either candidates for immunotherapy or treated with immunotherapy for their inhalant allergies. The target audience is all clinicians involved in the administration of immunotherapy. This guideline is intended to focus on evidence-based quality improvement opportunities judged most important by the guideline development group (GDG). It is not intended to be a comprehensive, general guide regarding the management of inhaled allergies with immunotherapy. The statements in this guideline are not intended to limit or restrict care provided by clinicians based on their experience and assessment of individual patients. ACTION STATEMENTS: The GDG made a strong recommendation that (Key Action Statement [KAS] 10) the clinician performing allergy skin testing or administering AIT must be able to diagnose and manage anaphylaxis. The GDG made recommendations for the following KASs: (KAS 1) Clinicians should offer or refer to a clinician who can offer immunotherapy for patients with AR with or without AA if their patients' symptoms are inadequately controlled with medical therapy, allergen avoidance, or both, or have a preference for immunomodulation. (KAS 2A) Clinicians should not initiate AIT for patients who are pregnant, have uncontrolled asthma, or are unable to tolerate injectable epinephrine. (KAS 3) Clinicians should evaluate the patient or refer the patient to a clinician who can evaluate for signs and symptoms of asthma before initiating AIT and for signs and symptoms of uncontrolled asthma before administering subsequent AIT. (KAS 4) Clinicians should educate patients who are immunotherapy candidates regarding the differences between SCIT and SLIT (aqueous and tablet) including risks, benefits, convenience, and costs. (KAS 5) Clinicians should educate patients about the potential benefits of AIT in (1) preventing new allergen sensitizations, (2) reducing the risk of developing AA, and (3) altering the natural history of the disease with continued benefit after discontinuation of therapy. (KAS 6) Clinicians who administer SLIT to patients with seasonal AR should offer pre- and co-seasonal immunotherapy. (KAS 7) Clinicians prescribing AIT should limit treatment to only those clinically relevant allergens that correlate with the patient's history and are confirmed by testing. (KAS 9) Clinicians administering AIT should continue escalation or maintenance dosing when patients have local reactions (LRs) to AIT. (KAS 11) Clinicians should avoid repeat allergy testing as an assessment of the efficacy of ongoing AIT unless there is a change in environmental exposures or a loss of control of symptoms. (KAS 12) For patients who are experiencing symptomatic control from AIT, clinicians should treat for a minimum duration of 3 years, with ongoing treatment duration based on patient response to treatment. The GDG offered the following KASs as options: (KAS 2B) Clinicians may choose not to initiate AIT for patients who use concomitant beta-blockers, have a history of anaphylaxis, have systemic immunosuppression, or have eosinophilic esophagitis (SLIT only). (KAS 8) Clinicians may treat polysensitized patients with a limited number of allergens.
引用
- Gurgel RK, Baroody FM, Damask CC, et al. Clinical Practice Guideline: Immunotherapy for Inhalant Allergy. Otolaryngol Head Neck Surg. 2024. PMID: 38408152. doi:10.1002/ohn.648
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。